SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM (vepdegestrant), following the early termination…

Read the full release →

News provided by PR Newswire.